Staphylococcus epidermidis produces a cell-associated proteinaceous fraction which causes bone resorption by a prostanoid-independent mechanism: relevance to the treatment of infected orthopaedic implants.
Staphylococcus epidermidis is the most commonly isolated coagulase-negative staphylococcus from the skin, gut and upper respiratory tract. Although it is less virulent than Staphylococcus aureus, it has emerged in recent years as an important causative agent of infections associated with metal implants, prosthetic devices and i.v. lines. We have previously demonstrated that a saline wash of S. aureus contained proteins which had potent bone-resorbing activity in vitro. The purpose of this study was to determine whether gently washing S. epidermidis in saline also released osteolytically active proteins. The so-called surface-associated material (SAM) eluted from S. epidermidis in saline was able to induce osteolysis, and activity was heat and trypsin sensitive, suggesting that the active component was proteinaceous. Fractionation studies have suggested that activity is due to a small number of cationic proteins. This SAM-induced bone resorption was not inhibited by the cyclo-oxygenase inhibitor, indomethacin, or the 5-lipoxygenase inhibitors BWA70C and MK886. However, it was partially inhibited by high concentrations of interleukin-1 receptor antagonist and was completely blocked by a neutralizing antibody to tumour necrosis factor-alpha. Thus, the SAM from this organism is a potent osteolytic agent which differs from that of S. aureus SAM in not being inhibited by cyclo-oxygenase inhibitors. As adjunctive therapy is becoming necessary in infectious diseases, either as a result of the side-effects of antibiotics or their lack of efficacy, consideration should be given to the future treatment of bone infections with staphylococci in the light of the different mechanisms of action of the surface proteins produced by these bacteria.
Meghji
S
S
Maxillofacial Surgery Research Unit, Eastman Dental Institute, University College London.
Crean
S J
SJ
Nair
S
S
Wilson
M
M
Poole
S
S
Harris
M
M
Henderson
B
B
D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D002458:Cell Fractionation; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007595:Joint Prosthesis; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D051379:Mice; D011453:Prostaglandins / Q000378:metabolism*; D019736:Prostheses and Implants / Q000382:microbiology*; D012886:Skull / Q000166:cytology / Q000378:metabolism / Q000382:microbiology; D013203:Staphylococcal Infections / Q000378:metabolism*; D013212:Staphylococcus epidermidis / Q000737:chemistry / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D002722:Chlorobenzenes
D002118:Calcium; D016861:Cyclooxygenase Inhibitors; D007211:Indoles; D007213:Indomethacin; D016859:Lipoxygenase Inhibitors; D011453:Prostaglandins; D014409:Tumor Necrosis Factor-alpha; C060893:MK-886; D002722:Chlorobenzenes